SNSE
NASDAQSensei Biotherapeutics Inc.
News · 26 weeks51-25%
2025-12-142026-06-07
Mix3990d
- SEC Filings18(46%)
- Other10(26%)
- Insider7(18%)
- Analyst3(8%)
- M&A1(3%)
Latest news
25 items- PRSensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) today announced that, effective on June 1, 2026, the Compensation Committee of Sensei's Board of Directors granted three new employees options to purchase an aggregate of 19,300 shares of the Company's common stock in connection with their employment (collectively, the "Option Awards"). The Option Awards were granted pursuant to the Company's 2026 Inducement Plan as a material inducement to the individuals entering employment with Sensei in accordance with Nasdaq Listing Rule 5635(c)(4). The Option Awards have an exercise price of $19.79, which is equal to the closing price of Sensei's common stock on June 1, 2026, and will vest, with respect to
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Sensei Biotherapeutics Inc.SCHEDULE 13G/A - Sensei Biotherapeutics, Inc. (0001829802) (Subject)
- SECAmendment: SEC Form 10-K/A filed by Sensei Biotherapeutics Inc.10-K/A - Sensei Biotherapeutics, Inc. (0001829802) (Filer)
- SECAmendment: SEC Form S-3/A filed by Sensei Biotherapeutics Inc.S-3/A - Sensei Biotherapeutics, Inc. (0001829802) (Filer)
- INSIDERLarge owner Cambrian Biopharma Inc sold $500,543 worth of shares (25,000 units at $20.02), decreasing direct ownership by 16% to 130,142 units (SEC Form 4)4 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)
- INSIDERLarge owner Peyer James sold $500,543 worth of shares (25,000 units at $20.02), decreasing direct ownership by 16% to 130,142 units (SEC Form 4)4 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)
- ANALYSTCantor Fitzgerald initiated coverage on Sensei BiotherapeuticsCantor Fitzgerald initiated coverage of Sensei Biotherapeutics with a rating of Overweight
- SECSEC Form DEFA14A filed by Sensei Biotherapeutics Inc.DEFA14A - Sensei Biotherapeutics, Inc. (0001829802) (Filer)
- SECSEC Form 8-K filed by Sensei Biotherapeutics Inc.8-K - Sensei Biotherapeutics, Inc. (0001829802) (Filer)
- ANALYSTCitigroup initiated coverage on Sensei Biotherapeutics with a new price targetCitigroup initiated coverage of Sensei Biotherapeutics with a rating of Buy and set a new price target of $55.00
- SECSEC Form DEFA14A filed by Sensei Biotherapeutics Inc.DEFA14A - Sensei Biotherapeutics, Inc. (0001829802) (Filer)
- SECSEC Form 8-K filed by Sensei Biotherapeutics Inc.8-K - Sensei Biotherapeutics, Inc. (0001829802) (Filer)
- INSIDERLarge owner Millennium Management Llc bought $141,364 worth of shares (4,215 units at $33.54) and sold $538,114 worth of shares (17,076 units at $31.51) (SEC Form 4)4 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)
- INSIDERLarge owner Millennium Management Llc bought $818,257 worth of shares (30,585 units at $26.75) and sold $89,390 worth of shares (3,250 units at $27.50) (SEC Form 4)4 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)
- INSIDERSEC Form 4 filed by Sensei Biotherapeutics Inc.4 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Sensei Biotherapeutics Inc.SCHEDULE 13G - Sensei Biotherapeutics, Inc. (0001829802) (Subject)
- SECSEC Form SCHEDULE 13G filed by Sensei Biotherapeutics Inc.SCHEDULE 13G - Sensei Biotherapeutics, Inc. (0001829802) (Subject)
- SECSEC Form S-8 filed by Sensei Biotherapeutics Inc.S-8 - Sensei Biotherapeutics, Inc. (0001829802) (Filer)
- SECSEC Form 10-Q filed by Sensei Biotherapeutics Inc.10-Q - Sensei Biotherapeutics, Inc. (0001829802) (Filer)
- SECSensei Biotherapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Sensei Biotherapeutics, Inc. (0001829802) (Filer)
- PRSensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateFirst patient dosed in Phase 1b/2 trial of PIKTOR in HR+/HER2- advanced breast cancer Topline Phase 2 data in patients with advanced endometrial cancer expected in second half 2026 Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update. "The first quarter of 2026 was transformational for the Company, with the acquisition of Faeth Therapeutics and the concurrent $200 million private placement in February, supported by a group of leading life sciences investors," said Christopher Gerry, President & General Counsel of Sensei Biotherapeutics. "This acquisition and injection of new capital will
- PR"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming TherapiesIssued on behalf of GT Biopharma, Inc. After more than $1.7 billion in dealmaking and a string of Phase 1 starts in 2026, prostate, pancreatic, and other historically immunotherapy-resistant solid tumors are suddenly among the busiest battlegrounds in oncology — and a new natural killer cell engager just joined the field SAN FRANCISCO, May 14, 2026 (GLOBE NEWSWIRE) -- World Street Intelligence News Commentary — Until very recently, the immuno-oncology revolution had largely passed several of the most lethal solid tumor categories by. Checkpoint inhibitors, which transformed outcomes in melanoma, lung cancer, and renal cell carcinoma, have struggled to deliver meaningful benefit for the m
- PRSensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast CancerPIKTOR is an investigational all-oral, multi-node inhibitor targeting escape routes in the PI3K/AKT/mTOR pathway that single-node inhibitors leave open Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical-stage biotechnology company, announced today that the first patient was dosed in Study FTH-PIK-101 (NCT07558733), a Phase 1b/2 trial of PIKTOR in patients with HR+/HER2- advanced breast cancer. PIKTOR, an investigational, all-oral combination of serabelisib and sapanisertib, is designed to inhibit multiple nodes of the PI3K/AKT/mTOR pathway through PI3K-alpha and dual mTORC1/2 targeting, and became Sensei's lead program after the company acquired Faeth Therapeutics in February 2026.
- SECSEC Form 144 filed by Sensei Biotherapeutics Inc.144 - Sensei Biotherapeutics, Inc. (0001829802) (Subject)
- SECSEC Form S-3 filed by Sensei Biotherapeutics Inc.S-3 - Sensei Biotherapeutics, Inc. (0001829802) (Filer)
SNSE FAQ
7 questionsWhat does Sensei Biotherapeutics Inc. do?
Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company, engages in the discovery and development of therapies with an initial focus on treatments for cancer. The company develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response. It is engineering ImmunoPhage product candidates to directly target antigen presenting cells and modulate the tumor microenvironment through the targeted use of nanobodies which further enhances therapeutic activity. Sensei...Where does SNSE stock trade?
Sensei Biotherapeutics Inc. (SNSE) is listed on NASDAQ.What sector and industry is SNSE in?
Sensei Biotherapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Sensei Biotherapeutics Inc. go public?
Sensei Biotherapeutics Inc. (SNSE) completed its IPO in 2021.What are analysts saying about SNSE?
Sensei Biotherapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Cantor Fitzgerald: Overweight on 2026-05-29. Recent price targets range from $500.00 to $1400.00.What companies are similar to SNSE?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare SNSE side-by-side with any of them on Quantisnow.How can I track SNSE on Quantisnow?
Quantisnow aggregates Sensei Biotherapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SNSE to receive live email and push alerts on every new disclosure.